MedTrace Logo

Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus

NCT04336488 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2020-06-19

No results posted yet for this study

Summary

The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.

Conditions

  • Oral Lichen Planus

Interventions

DRUG

Matrix Metalloproteinase Inhibitors (Orochem)

topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus

DRUG

Kenacort A,

topical application of both drugs 3 times daily for 3 weeks as an active control

Sponsors & Collaborators

  • Jaylane kadry Ghonima

    lead OTHER

Principal Investigators

  • Hossam H. AlSabbagh, As. lecturer · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2020-06-01
Completion
2020-07-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04336488 on ClinicalTrials.gov